Survivin in solid tumors: Rationale for development of inhibitors

Current Oncology Reports

Volumn 14, Issue 2, 2012, Pages 120-128

  Church, David N ^a   Talbot, Denis C ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Antisense oligonucleotide; Apoptosis; BIRC5; Cancer; Cell cycle; Solid tumours; Survivin

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CARBOPLATIN; CYTARABINE; DENDRITIC CELL VACCINE; DOCETAXEL; EZN 3042; GATAPARSEN; IDARUBICIN; PACLITAXEL; PEPTIDE VACCINE; SEPANTRONIUM BROMIDE; SHEPHERDIN; SPC 3042; SURVIVIN; SURVIVIN INHIBITOR; TEMOZOLOMIDE; TERAMEPROCOL; UNCLASSIFIED DRUG; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; APOPTOSIS; ARTHRALGIA; ARTICLE; BREAST METASTASIS; CANCER PROGNOSIS; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CELL INVASION; CELL PROLIFERATION; CHEMOSENSITIVITY; CHILL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; INHIBITION KINETICS; KIDNEY INJURY; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMATITIS; UPREGULATION; CELL CYCLE; CLINICAL TRIAL (TOPIC); DRUG ANTAGONISM; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL CYCLE; CLINICAL TRIALS AS TOPIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS;

EID: 84860862938     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0215-2     Document Type: Article

References (100)

1. Altieri DC. New wirings in the survivin networks. Oncogene. 2008;27: 6276-84.
2. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8: 61-70. Excellent review which presents an elegant summary of current knowledge of survivin biology.
3. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer. 2005;4: 11.
4. Badran A, Yoshida A, Ishikawa K, et al. Identification of a novel splice variant of the human anti-apoptopsis gene survivin. Biochem Biophys Res Commun. 2004;314: 902-7. (Pubitemid 38112885)
5. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59: 6097-102. (Pubitemid 30035627)
6. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DCC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol. 1998;152: 43-9. (Pubitemid 28028045)
7. Uren AG, Wong L, Pakusch M, et al. Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype. Curr Biol. 2000;10: 1319-28.
8. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3: 917-21. (Pubitemid 27353455)
9. Zhang T, Otevrel T, Gao Z, Ehrlich SM, Fields JZ, Boman BM. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 2001;61: 8664-7. (Pubitemid 34013874)
10. Fukuda S, Pelus LM. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34 (+) cells by hematopoietic growth factors: implication of surviving expression in normal hematopoiesis. Blood. 2001;98: 2091-100.
11. Gianani R, Jarboe E, Orlicky D, et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol. 2001;32: 119-25. (Pubitemid 32150638)
12. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006;5: 1087-98. (Pubitemid 43881300)
13. Altieri DC. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006;18: 609-15. (Pubitemid 44692469)
14. Lens SM, Vader G, Medema RH. The case for Survivin as mitotic regulator. Curr Opin Cell Biol. 2006;18: 616-22. (Pubitemid 44711886)
15. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood. 2003;101: 1535-42. (Pubitemid 36182531)
16. Vaira V, Lee CW, Goel HL, Bosari S, Languino LR, Altieri DC. Regulation of survivin expression by IGF-1/mTOR signaling. Oncogene. 2007;26: 2678-84. (Pubitemid 46663841)
17. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res. 2008;14: 1581-9. (Pubitemid 351413943)
18. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000;113 (Pt 23): 4363-71. (Pubitemid 32000697)
19. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science. 2005;310: 1499-504. (Pubitemid 41746347)
20. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34 (cdc2) survival checkpoint in cancer. Cancer Cell. 2002;2: 43-54. (Pubitemid 41043987)
21. Wheatley SP, Barrett RM, Andrews PD, et al. Phosphorylation by aurora-B negatively regulates survivin function during mitosis. Cell Cycle. 2007;6: 1220-30. (Pubitemid 47327989)
22. Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase A regulates cytoprotection. Mol Cell. 2007;27: 17-28. (Pubitemid 46991388)
23. Verdecia MA, Huang H, Dutil E, Kaiser DA, Hunter T, Noel JP. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement. Nat Struct Biol. 2000;7: 602-8. (Pubitemid 30445919)
24. Chantalat L, Skoufias DA, Kleman JP, Jung B, Dideberg O, Margolis RL. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions. Mol Cell. 2000;6: 183-9.
25. Jeyaprakash AA, Klein UR, Lindner D, Ebert J, Nigg EA, Conti E. Structure of a Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together. Cell. 2007;131: 271-85. (Pubitemid 47576137)
26. Kang BH, Altieri DC. Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J Biol Chem. 2006;281: 24721-7. (Pubitemid 44274246)
27. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci U S A. 2003;100: 13791-6. (Pubitemid 37499145)
28. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3: 46-54. (Pubitemid 37328886)
29. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5: 897-907. (Pubitemid 39486541)
30. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene. 2003;22: 8581-9. (Pubitemid 38019195)
31. Tamm I, Wang Y, Sausville E, et al. IAP-family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58: 5315-20. (Pubitemid 28551107)
32. Banks DP, Plescia J, Altieri DC, et al. Survivin does not inhibit caspase-3 activity. Blood. 2000;96: 4002-3.
33. Li C, Wu Z, Liu M, Pazgier M, Lu W. Chemically synthesized human survivin does not inhibit caspase-3. Protein Sci. 2008;17: 1624-9.
34. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;7: 988-94. (Pubitemid 44480512)
35. Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003;22: 2729-40. (Pubitemid 36712369)
36. Li F, Ambrosini G, Chu EY, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998;396: 580-4. (Pubitemid 28563719)
37. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci U S A. 2004;101: 15100-5. (Pubitemid 39391725)
38. Bolton MA, Lan W, Powers SE, McCleland ML, Kuang J, Stukenberg PTC. Aurora B kinase exists in a complex with surviving and INCENP and its kinase activity is stimulated by surviving binding and phosphorylation. Mol Biol Cell. 2002;13: 3064-77. (Pubitemid 35034246)
39. Wheatley SP, Carvalho A, Vagnarelli P, Earnshaw WC. INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis. Curr Biol. 2001;11: 886-90. (Pubitemid 32532816)
40. Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A, Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell. 2004;118: 187-202. (Pubitemid 38962575)
41. Sandall S, Severin F, McLeod IX, et al. A Bir1-Sli15 complex connects centromeres to microtubules and is required to sense kinetochore tension. Cell. 2006;127: 1179-91. (Pubitemid 44894521)
42. Rosa J, Canovas P, Islam A, Altieri DC, Doxsey SJ. Survivin modulates microtubule dynamics and nucleation throughout the cell cycle. Mol Biol Cell. 2006;17: 1483-93. (Pubitemid 43376565)
43. Ghosh JC, Dohi T, Raskett CM, Kowalik TF, Altieri DC. Activated checkpoint kinase 2 provides a survival signal for tumor cells. Cancer Res. 2006;66: 11576-9. (Pubitemid 46094165)
44. O'Connor DS, Schechner JS, Adida C, et al. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am J Pathol. 2000;156: 393-8. (Pubitemid 30643793)
45. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci U S A. 2002;99: 4349-54. (Pubitemid 34285988)
46. Zwerts F, Lupu F, De Vriese A, et al. Lack of endothelial cell survivin causes embryonic defects in angiogenesis, cardiogenesis, and neural tube closure. Blood. 2007;109: 4742-52. (Pubitemid 46827767)
47. Mehrotra S, Languino LR, Raskett CM, Mercurio AM, Dohi T, Altieri DC. IAP regulation of metastasis. Cancer Cell. 2010;17: 53-64. Exciting paper demonstrating new role for survivin in promotion of tumor invasion and metastasis.
48. Velculescu VE, Madden SL, Zhang L, et al. Analysis of human transcriptomes. Nat Genet. 1999;23: 387-8.
49. Adida C, Berrebi D, Peuchmaur M, Reyes-Mugica M, Altieri DC. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet. 1998;351: 882-3. (Pubitemid 28121185)
50. Chakravarti A, Noll E, Black PM, et al. Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J Clin Oncol. 2002;20: 1063-8. (Pubitemid 34141851)
51. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998;58: 1808-12. (Pubitemid 28217451)
52. Monzo M, Rosell R, Felip E, et al. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol. 1999;17: 2100-4. (Pubitemid 29318841)
53. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res. 2000;6: 127-34. (Pubitemid 30064984)
54. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998;58: 5071-4. (Pubitemid 28521163)
55. Cohen C, Lohmann CM, Cotsonis G, Lawson D, Santoianni R. Survivin expression in ovarian carcinoma: correlation with apoptotic markers and prognosis. Mod Pathol. 2003;16: 574-83. (Pubitemid 36718439)
56. Sarela AI, Verbeke CS, Ramsdale J, Davies CL, Markham AF, Guillou PJC. Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma. Br J Cancer. 2002;86: 886-92. (Pubitemid 34271023)
57. Grabowski P, Kuhnel T, Muhr-Wilkenshoff F, et al. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer. 2003;88: 115-9. (Pubitemid 36241227)
58. NasrMR, El-ZammarO. Comparison of pHH3, Ki-67, and surviving immunoreactivity in benign andmalignantmelanocytic lesions.Am J Dermatopathol. 2008;30: 117-22.
59. HoffmanWH, Biade S, Zilfou JT, Chen J, MurphyM. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem. 2002;277: 3247-57. (Pubitemid 34953189)
60. Guha M, Plescia J, Leav I, Li J, Languino LR, Altieri DC. Endogenous tumor suppression mediated by PTEN involves survivin gene silencing. Cancer Res. 2009;69: 4954-8.
61. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA. Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem. 2004;279: 40511-20. (Pubitemid 39287642)
62. Wang RH, Zheng Y, Kim HS, et al. Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell. 2008;32: 11-20.
63. Pise-Masison CA, Radonovich M, Dohoney K, et al. Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viability. Blood. 2009;113: 4016-26.
64. Nguyen HG, Ravid K. Tetraploidy/aneuploidy and stem cells in cancer promotion: The role of chromosome passenger proteins. J Cell Physiol. 2006;208: 12-22. (Pubitemid 43848985)
65. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007;67: 339-45. (Pubitemid 46142793)
66. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat Med. 2007;13: 820-7. (Pubitemid 47038193)
67. You L, He B, Xu Z, et al. Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene. 2004;23: 6170-4. (Pubitemid 39178870)
68. Sommer KW, Schamberger CJ, Schmidt GE, Sasgary S, Cerni C. Inhibitor of apoptosis protein (IAP) survivin is upregulated by oncogenic c-H-Ras. Oncogene. 2003;22: 4266-80. (Pubitemid 36876247)
69. Guha M, Xia F, Raskett CM, Altieri DC. Caspase 2-mediated tumor suppression involves survivin gene silencing. Oncogene. 2010;29: 1280-92.
70. Shinohara ET, Gonzalez A, Massion PP, et al. Nuclear surviving predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer. 2005;103: 1685-92. (Pubitemid 40490030)
71. Islam A, Kageyama H, Takada N, et al. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene. 2000;19: 617-23. (Pubitemid 30102912)
72. Kato J, Kuwabara Y, Mitani M, et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer. 2001;95: 92-5. (Pubitemid 32187079)
73. Zhang M, Latham DE, Delaney MA, Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene. 2005;24: 2474-82. (Pubitemid 40593038)
74. Lu J, Tan M, Huang WC, et al. Mitotic deregulation by surviving in ErbB2-overexpressing breast cancer cells contributes to Taxol resistance. Clin Cancer Res. 2009;15: 1326-34.
75. Wall NR, O'Connor DS, Plescia J, Pommier Y, Altieri DC. Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. 2003;63: 230-5. (Pubitemid 36070444)
76. Kappler M, Bache M, Bartel F, et al. Knockdown of surviving expression by small interfering RNA reduces the clonogenic survival of human sarcoma cell lines independently of p53. Cancer Gene Ther. 2004;11: 186-93. (Pubitemid 38280521)
77. Grossman D, McNiff JM, Li F, Altieri DC. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol. 1999;113: 1076-81. (Pubitemid 30013356)
78. Yamanaka K, Nakata M, Kaneko N, et al. YM155, a selective survivin suppressant, inhibits tumor spread and prolongs survival in a spontaneous metastatic model of human triple negative breast cancer. Int J Oncol. 2011;39: 569-75.
79. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res. 2003;9: 2683-92. (Pubitemid 36842114)
80. Hayashi N, Asano K, Suzuki H, et al. Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo. Prostate. 2005;65: 10-9. (Pubitemid 41318826)
81. Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, et al. Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer. Clin Cancer Res. 2011;17: 3716-26.
82. Iwasa T, Okamoto I, Takezawa K, et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer. 2010;103: 36-42.
83. Nakahara T, Yamanaka K, Hatakeyama S, et al. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs. 2011;22: 454-62.
84. Yamanaka K, Nakahara T, Yamauchi T, et al. Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressant, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models. Clin Cancer Res. 2011;17: 5423-31.
85. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BK. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther. 2011;10: 221-32.
86. Talbot DC, Ranson M, Davies J, et al. Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: aproof-of-concept, first-in-human dose study. Clin Cancer Res. 2010;16: 6150-6158. Phase I, proof-of-principle study of surviving inhibition with LY2181308, showing acceptable toxicity and confirming target inhibtion.
87. Tanioka M, Nokihara H, Yamamoto N, et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68: 505-11.
88. Hansen JB, Fisker N, WestergaardM, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther. 2008;7: 2736-45.
89. Nakahara T, Takeuchi M, Kinoyama I, et al. YM155, a novel smallmolecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res. 2007;67: 8014-21. (Pubitemid 47395135)
90. Tolcher AW, Mita A, Lewis LD, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26: 5198-5203. Phase I study of YM155 in humans showing acceptable toxicity and therapeutic efficacy in heavily pretreated patients.
91. Satoh T, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 2009;15: 3872-80.
92. Giaccone G, Zatloukal P, Roubec J, et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol. 2009;27: 4481-6.
93. Chang CC, Heller JD, Kuo J, Huang RC. Tetra-O-methyl nordihydroguaiaretic acid induces growth arrest and cellular apoptosis by inhibiting Cdc2 and survivin expression. Proc Natl Acad Sci U S A. 2004;101: 13239-44. (Pubitemid 39209649)
94. Khanna N, Dalby R, Tan M, Arnold S, Stern J, Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol Oncol. 2007;107: 554-62. (Pubitemid 350160872)
95. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res. 2001;61: 869-72. (Pubitemid 32175146)
96. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted Tcell epitopes in situ as well as ex vivo in cancer patients. Cancer Res. 2001;61: 5964-8. (Pubitemid 32768582)
97. Andersen MH, Soerensen RB, Becker JC. thor Straten P. HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer. J Transl Med. 2006;4: 38.
98. Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005;7: 457-68. (Pubitemid 40719129)
99. Siegelin MD, Plescia J, Raskett CM, Gilbert CA, Ross AH, Altieri DC. Global targeting of subcellular heat shock protein-90 networks for therapy of glioblastoma. Mol Cancer Ther. 2010;9: 1638-46.
100. Herrington WG, Talbot DC, Lahn MM, et al. Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma. Am J Kidney Dis. 2011;57: 300-3.